CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 217 enrolled
Drug / intervention
Orlistat/Meal Replacement/Lifestyle Modification +2 moredrug
Likely dose
Orlistat/Meal Replacement/Lifestyle Modification 60 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00704912
NCT00704912Phase 2Completed

Treatment of Hyperandrogenism vs. Insulin Resistance in Infertile PCOS Women

Milton S. Hershey Medical Center·interventional·Posted Jun 25, 2008·Updated Nov 7, 2016

In Brief

A Phase 2 clinical trial evaluating Orlistat/Meal Replacement/Lifestyle Modification, Loestrin 1/20, and 1 other intervention for Polycystic Ovary Syndrome. Completed, enrolled 217 participants across 2 sites.

Detailed Summary

The goal of this three-armed randomized controlled trial is to establish the relative roles of treatment of hyperandrogenism versus obesity (as the largest modifiable factor contributing to insulin resistance) in treating infertility and improving pregnancy outcomes among obese PCOS women. The investigators hypothesize that the key to restoring ovulation leading to live birth is to correct hyperandrogenism with oral contraceptive pills, but the key to avoiding later pregnancy complications is to improve insulin sensitivity with weight loss.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 25, 2008
Enrollment StartSep 1, 2008
Primary CompletionMar 1, 2014
TodayJul 2, 2026
Enrollment to primary: 5.5 yearsPosted 18.0 years ago

Interventions

Orlistat/Meal Replacement/Lifestyle Modificationdrug

Orlistat will be given at 60 mg three times per day (1 tablet 3 times a day) before meals, i.e., breakfast, lunch, and dinner.

Loestrin 1/20drug

Patients will be started on a low dose containing OCP for a continuous 4 month period.

Combination of treatmentsdrug

Medications will be administered as described for the other 2 arms.